Researchers have linked Novo Nordisk’s semaglutide to a 40% to 70% reduction in the risk of Alzheimer’s disease diagnosis in ...

Now they are being found to treat cardiovascular and kidney disease, and are being tested for Alzheimer ... Already one in ...

Oral semaglutide is currently approved under the brand name Rybelsus ® as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Based on these findings, ...

Viking Therapeutics Inc.'s stock soared 18% Thursday, after the biotech, which is developing a weight-loss drug in pill form that has raised high hopes among analysts and investors, posted earnings ...

A new study is adding to evidence that GLP-1 drugs such as Novo Nordisk's semaglutide and Eli Lilly's tirzepatide could also ...

The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer’s diagnosis in ...

Patients taking Novo Nordisk A/S’s Ozempic were at significantly reduced risk of being diagnosed with Alzheimer’s, according ...

executive vice president and head of Development at Novo Nordisk. "Approximately one in three adults with type 2 diabetes also have cardiovascular disease; therefore, it is crucial to have therapies ...

The diabetes and weight loss drug Ozempic could lower the risk of Alzheimer’s disease among people with type 2 diabetes, ...

Many menopausal women experience joint pain due to a drop in oestrogen, which increases inflammation. Cold weather can also ...

and has also moved into phase 3 obesity trials – but took the opportunity to highlight Boehringer’s pipeline in other areas. Top of the agendas was chronic kidney disease (CKD), an area where ...

Otsuka is hoping to file for approval of its anti-APRIL antibody sibeprenlimab as a treatment for kidney disorder IgA nephropathy (IgAN) after the drug hit the target in a phase 3 trial.